Cocrystal Pharma, Inc. Income Statement
COCP|4 years of annual SEC 10-K data (FY2012-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Revenue increased 0.0% from FY2019 to FY2020.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2019 | FY2012 |
|---|---|---|---|---|
| Revenue | - | $6.6M | $6.6M | - |
| Cost of Revenue | - | - | - | $405.9K |
| Gross Profit | - | - | - | $7.2M |
| SG&A Expense | $5.4M | $4.9M | $4.4M | $2.1M |
| R&D Expense | $8.8M | $4.0M | $4.7M | $489.3K |
| Operating Income | -$14.2M | -$48.4M | -$62.9M | -$2.6M |
| Interest Expense | $4.0K | $19.0K | $58.0K | -$5.2M |
| Income Tax | - | - | -$13.6M | - |
| Net Income | -$14.2M | -$48.2M | -$49.0M | -$8.0M |
| EPS (Basic) | - | - | - | -$0.11 |
| EPS (Diluted) | -$0.17 | -$1.51 | -$1.75 | -$0.11 |
| Shares Outstanding | 70.4M | 35.1M | 29.9M | 55.2M |
| Operating Margin | - | -737.5% | -958.6% | - |
| Profit Margin | - | -733.8% | -747.2% | - |